

Obesity Therapeutics Market to Reach USD\$ 63.75 Billion by 2032, Rising Obesity Rates and Advanced Pharmacotherapies

Obesity Therapeutics Market Outlook 2033 | Global Market Trends, Drivers & Forecast

AUSTIN, TX, UNITED STATES, November 12, 2025 /EINPresswire.com/ -- Market Size and Growth

According to DataM Intelligence, the global [obesity therapeutics](#) market size reached USD 9.19 billion in 2023 and increased to USD 11.03 billion in 2024.

It is projected to grow significantly, reaching USD \$63.75 billion by 2033, with a compound annual growth rate (CAGR) of 21.6% during the forecast period from 2025 to 2033. Increasing obesity prevalence worldwide, coupled with advancements in pharmacological treatments such as GLP-1 receptor agonists, is driving rapid market expansion.

“


U.S. obesity therapeutics market reached US\$ 11.03 Billion in 2024 and is projected to hit US\$ 63.75 Billion by 2033, growing at a CAGR of 21.6% (2025–2033).”

DataM Intelligence 4Market Research LLP

The surge in obesity-related health complications like diabetes, cardiovascular diseases, and metabolic syndrome is accelerating demand for effective therapeutics. Innovations in injectable and oral [obesity drugs](#) are improving efficacy and patient adherence, supported by rising health awareness and government initiatives promoting weight management programs.

Growth Drivers

- Global obesity rates surpassed 650 million adults in 2024, creating an urgent need for therapeutic intervention.
- [GLP-1 analogues](#) such as Mounjaro and Wegovy have revolutionized treatment, with improved weight loss outcomes and tolerability.



- Increased insurance coverage and healthcare infrastructure expansion facilitate broader patient access to obesity drugs.
- Telemedicine and digital health tools enhance patient monitoring and treatment compliance.
- Rising investments from pharma companies and growing pipeline of next-generation obesity therapeutics fuel innovation.

Download PDF Brochure:
<https://www.datamintelligence.com/download-sample/competitive-landscape-of-the-global-obesity-therapeutics-market>

Browse in-depth TOC on "Obesity Therapeutics Market"
70 – Tables
66 – Figures
195 – Pages

Market Segmentation Analysis
By Drug Type

- GLP-1 receptor agonists dominate with 45% market share in 2024, projected to reach USD 12 billion by 2032 at an 11.7% CAGR.
- Appetite suppressants, combination therapies, and lipase inhibitors account for the remainder, growing steadily.

By Route of Administration

- Injectable drugs hold 60% market share, favored for high efficacy and patient outcomes.
- Oral formulations are gaining market traction due to ease of use and patient preference.


By End-User

- Hospitals and specialty clinics lead with 70% market share, while outpatient and home care segments are expanding.

Regional Insights

North America

The North American obesity therapeutics market was valued at USD 5 billion in 2024 and is



projected to reach USD 11.8 billion by 2032, growing at a CAGR of 11.2%. High obesity prevalence, reimbursement policies, and early adoption of innovative therapies drive this growth.

Europe

Europe holds 25% market share, with increasing government programs supporting obesity management and rising awareness fueling adoption.

Asia-Pacific

Asia-Pacific is emerging rapidly, with growing urbanization, lifestyle changes, and healthcare investments expected to boost market growth at a CAGR of 12.5%.

Request for Customized Sample Report as per Your Business Requirement:

<https://www.datamintelligence.com/customize/competitive-landscape-of-the-global-obesity-therapeutics-market>

Key Players

The obesity therapeutics market is moderately consolidated, led by pharmaceutical giants such as:

Novo Nordisk || Eli Lilly || VIVUS LLC || Currax Pharmaceuticals LLC || GSK plc || Roche Laboratories Inc || AstraZeneca || Rhythm Pharmaceuticals, Inc || Takeda Pharmaceutical Company Limited, and KVK Tech, Inc. Companies focus on strategic partnerships, clinical trials, and product launches to expand their market presence.

Key Highlights:

- In 2024, North America held the largest revenue share of 48.5% in the global obesity therapeutics market.
- The Asia Pacific region emerged as the fastest-growing market, recording a CAGR of 7.7% in 2024.
- Based on drug class, the GLP-1 receptor agonists segment led the market with a 45.3% share in 2024.
- By route of administration, the oral segment dominated the market, accounting for a 41.3% share in 2024.

Recent Developments

- Eli Lilly announced new clinical trial results demonstrating Mounjaro's enhanced weight loss effects
- Novo Nordisk expanded indications for Wegovy to include adolescents with obesity
- Pfizer acquired a biotech firm specializing in combination obesity therapies

Market Outlook and Opportunities

The obesity therapeutics market is poised for sustained growth as unmet medical needs persist globally. Increasing adoption of personalized medicine, digital health integration, and emerging combination therapies are expected to unlock significant opportunities through 2032.

Key Forecast Indicators:

- GLP-1 receptor agonists to maintain dominance, with new entrants anticipated.
- Injectable therapies to hold majority share, while oral drugs gain share with innovation.
- North America and Asia-Pacific to remain fastest-growing regions.
- Increased collaboration between pharma and digital health companies to improve patient outcomes.

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer):

<https://www.datamintelligence.com/buy-now-page?report=competitive-landscape-of-the-global-obesity-therapeutics-market>

Conclusion

The global Obesity Therapeutics Market represents a critical frontier in combating the obesity epidemic, projected to more than double by 2032 from USD 11 billion in 2024. With advancements in pharmacotherapies, especially GLP-1 receptor agonists, and growing healthcare infrastructure, market leaders such as Novo Nordisk, Eli Lilly, and Pfizer are at the forefront of this transformation. DataM Intelligence expects obesity therapeutics to play an increasingly pivotal role in managing metabolic health worldwide.

Related Reports:

Weight Loss Therapeutics Market Size to Reach USD\$ 20.84 by 2032 – DataM Intelligence @ <https://www.datamintelligence.com/research-report/weight-loss-therapeutics-market>

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Set for Rapid Growth Through 2032 – DataM Intelligence @ <https://www.datamintelligence.com/research-report/metabolic-dysfunction-associated-steatohepatitis-treatment-market>

Injectable Drug Delivery Market to Surpass USD\$ 1258.4 million by 2032 – DataM Intelligence @ <https://www.datamintelligence.com/research-report/injectable-drug-delivery-market>

About DataM Intelligence

DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as

nutraceuticals and AI-driven health innovations.

Sai Kiran

DataM Intelligence 4market Research LLP

+1 877-441-4866

sai.k@datamintelligence.com

Visit us on social media:

[LinkedIn](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/866566456>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.